Details for New Drug Application (NDA): 202294
✉ Email this page to a colleague
The generic ingredient in DEXLANSOPRAZOLE is dexlansoprazole. There are seventeen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the dexlansoprazole profile page.
Summary for 202294
Tradename: | DEXLANSOPRAZOLE |
Applicant: | Endo Operations |
Ingredient: | dexlansoprazole |
Patents: | 0 |
Pharmacology for NDA: 202294
Mechanism of Action | Proton Pump Inhibitors |
Medical Subject Heading (MeSH) Categories for 202294
Suppliers and Packaging for NDA: 202294
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
DEXLANSOPRAZOLE | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 202294 | ANDA | ENDO USA, Inc. | 49884-147 | 49884-147-11 | 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (49884-147-11) |
DEXLANSOPRAZOLE | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 202294 | ANDA | ENDO USA, Inc. | 49884-148 | 49884-148-09 | 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (49884-148-09) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, DELAYED RELEASE;ORAL | Strength | 60MG | ||||
Approval Date: | Apr 19, 2017 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, DELAYED RELEASE;ORAL | Strength | 30MG | ||||
Approval Date: | Jun 16, 2022 | TE: | AB | RLD: | No |
Complete Access Available with Subscription